CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...
State data from 2018 through 2022 shows prostate cancer is the leading cancer diagnosis in Cuyahoga County, yet 77% of cases ...
Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...
SAN FRANCISCO, September 29, 2025 — For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to ...
Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...
The ARID II trial investigates the Voro Urologic Scaffold's safety and efficacy in prostate cancer patients undergoing robotic-assisted radical prostatectomy. The scaffold aims to improve urinary ...
Developing a manual clinical trials screening process in a diverse southern gynecologic oncology practice in the Deep South. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
But as it turned out, his transition from military service to civilian life came with prostate cancer. It was during his ...
Prostate Biopsy Findings. PROSTATE biopsy under local anesthesia showed similar safety and detection outcomes, with better ...
A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.
MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results